# An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.

> **NCT00891046** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 270 (actual)

## Conditions studied

- Systemic Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Canakinumab

## Key facts

- **NCT ID:** NCT00891046
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2019-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891046, "An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00891046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*